ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Recursos principais

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
AI Entrar Premium IconPremium Help Menu
Índice Bovespa
124.698,04
0,92%
S&P 500
6.050,61
-0,39%
US Dollar vs BRL
6,1052
0,01%
Bitcoin
103.843,85
-2,18%
Brent Oil
73,035
-0,10%
As Melhores Corretoras Online
Registration Strip Icon for pro Negocie como um profissional: Aproveite discussões em tempo real e ideias que movimentam o mercado para superar a concorrência.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Avidity Biosciences Inc (RNA)

  7. Avidity Biosciences Inc (RNA) Notícias

RNA

Avidity Biosciences (RNA)

Avidity Biosciences Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:RNA
DataHoraFonteTítuloCódigoCompanhia
16/12/202418:29Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:RNAAvidity Biosciences Inc
13/12/202420:08Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RNAAvidity Biosciences Inc
26/11/202412:00PR Newswire (US)Avidity Biosciences to Participate in Upcoming Investor ConferenceNASDAQ:RNAAvidity Biosciences Inc
21/11/202418:05PR Newswire (US)Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:RNAAvidity Biosciences Inc
14/11/202411:39Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:RNAAvidity Biosciences Inc
13/11/202418:40Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:RNAAvidity Biosciences Inc
12/11/202409:06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RNAAvidity Biosciences Inc
12/11/202409:00PR Newswire (US)Avidity Biosciences Announces New Precision Cardiology Development Candidates to Treat Rare Genetic Cardiomyopathies and Provides First Look at Next-Generation Technology InnovationsNASDAQ:RNAAvidity Biosciences Inc
07/11/202418:05PR Newswire (US)Avidity Biosciences Reports Third Quarter 2024 Financial Results and Recent HighlightsNASDAQ:RNAAvidity Biosciences Inc
31/10/202410:00PR Newswire (US)Avidity Biosciences to Host Investor and Analyst Event Focused on Precision Cardiology Candidates and First Look at Next-Generation Technology Innovations on November 12, 2024NASDAQ:RNAAvidity Biosciences Inc
30/10/202409:00PR Newswire (US)Avidity Biosciences Pursues Potential Accelerated Approval Path with Initiation of Biomarker Cohort in FORTITUDE™ Trial for Delpacibart Braxlosiran (del-brax/AOC 1020) in People Living with Facioscapulohumeral Muscular DystrophyNASDAQ:RNAAvidity Biosciences Inc
03/10/202408:00PR Newswire (US)Avidity Biosciences Announces FDA Removed Partial Clinical Hold on Delpacibart Etedesiran (del-desiran/AOC 1001)NASDAQ:RNAAvidity Biosciences Inc
05/09/202410:00PR Newswire (US)Avidity Biosciences Joins Patient and Advocacy Communities in Raising Awareness During National Muscular Dystrophy Awareness MonthNASDAQ:RNAAvidity Biosciences Inc
28/08/202410:00PR Newswire (US)Avidity Biosciences to Participate in Upcoming Investor ConferencesNASDAQ:RNAAvidity Biosciences Inc
19/08/202410:00PR Newswire (US)Avidity Biosciences Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional SharesNASDAQ:RNAAvidity Biosciences Inc
15/08/202417:43Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:RNAAvidity Biosciences Inc
14/08/202421:30PR Newswire (US)Avidity Biosciences Announces Pricing of Upsized Public Offering of Common StockNASDAQ:RNAAvidity Biosciences Inc
09/08/202418:02Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:RNAAvidity Biosciences Inc
09/08/202417:23Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:RNAAvidity Biosciences Inc
09/08/202417:05PR Newswire (US)Avidity Biosciences Reports Second Quarter 2024 Financial Results and Recent HighlightsNASDAQ:RNAAvidity Biosciences Inc
09/08/202408:00PR Newswire (US)Avidity Biosciences Announces Positive AOC 1044 Data Demonstrated Significant Increase of 25% in Dystrophin Production and Reduction of Creatine Kinase Levels to Near Normal in People Living with Duchenne Muscular Dystrophy Amenable to Exon 44 Skipping inNASDAQ:RNAAvidity Biosciences Inc
05/08/202410:00PR Newswire (US)Avidity Biosciences Announces Appointment of John B. Moriarty, Jr. as Chief Legal OfficerNASDAQ:RNAAvidity Biosciences Inc
20/06/202410:00PR Newswire (US)Avidity Biosciences Partners with the FSHD Society to Raise Awareness of Facioscapulohumeral Muscular Dystrophy on World FSHD DayNASDAQ:RNAAvidity Biosciences Inc
17/06/202417:05PR Newswire (US)Avidity Biosciences, Inc. Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional SharesNASDAQ:RNAAvidity Biosciences Inc
13/06/202421:00PR Newswire (US)Avidity Biosciences, Inc. Announces Pricing of Public Offering of Common StockNASDAQ:RNAAvidity Biosciences Inc
12/06/202417:01PR Newswire (US)Avidity Biosciences, Inc. Announces Proposed Public Offering of Common StockNASDAQ:RNAAvidity Biosciences Inc
12/06/202408:00PR Newswire (US)Avidity Announces Unprecedented AOC 1020 Data from Phase 1/2 FORTITUDE™ Trial Demonstrating Greater Than 50 Percent Reduction in DUX4 Regulated Genes and Trends of Functional Improvement in People Living with Facioscapulohumeral Muscular DystrophyNASDAQ:RNAAvidity Biosciences Inc
29/05/202417:05PR Newswire (US)Avidity Biosciences to Present Preliminary Data from Phase 1/2 FORTITUDE™ Trial of AOC 1020 in People Living with Facioscapulohumeral Muscular Dystrophy at 31st Annual FSHD Society International Research CongressNASDAQ:RNAAvidity Biosciences Inc
16/05/202419:15Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:RNAAvidity Biosciences Inc
15/05/202410:10Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:RNAAvidity Biosciences Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:RNA

Seu Histórico Recente

BOV
ATOM3
ATOMPAR ON
BOV
IBOV
Índice Bovespa
BOV
TELB4
TELEBRAS PN
BOV
AZEV4
AZEVEDO PN
BOV
PRIO3
PETRORIO ON
BOV
COGN3
COGNA ON
BOV
BHIA3
Grupo Casas Bahia ON
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados